Cargando…
In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia
Multidrug-resistant (MDR) Pseudomonas aeruginosa has been declared a serious threat by the United States Centers for Disease Control and Prevention. Here, we used whole genome sequencing (WGS) to investigate recurrent P. aeruginosa bloodstream infections in a severely immunocompromised patient. The...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499174/ https://www.ncbi.nlm.nih.gov/pubmed/37712060 http://dx.doi.org/10.3389/fcimb.2023.1241608 |
_version_ | 1785105650375720960 |
---|---|
author | Spottiswoode, Natasha Hao, Samantha Sanchez-Guerrero, Estella Detweiler, Angela M. Mekonen, Honey Neff, Norma Macmillan, Henriette Schwartz, Brian S. Engel, Joanne DeRisi, Joseph L. Miller, Steven A. Langelier, Charles R. |
author_facet | Spottiswoode, Natasha Hao, Samantha Sanchez-Guerrero, Estella Detweiler, Angela M. Mekonen, Honey Neff, Norma Macmillan, Henriette Schwartz, Brian S. Engel, Joanne DeRisi, Joseph L. Miller, Steven A. Langelier, Charles R. |
author_sort | Spottiswoode, Natasha |
collection | PubMed |
description | Multidrug-resistant (MDR) Pseudomonas aeruginosa has been declared a serious threat by the United States Centers for Disease Control and Prevention. Here, we used whole genome sequencing (WGS) to investigate recurrent P. aeruginosa bloodstream infections in a severely immunocompromised patient. The infections demonstrated unusual, progressive increases in resistance to beta lactam antibiotics in the setting of active treatment with appropriate, guideline-directed agents. WGS followed by comparative genomic analysis of isolates collected over 44 days demonstrated in host evolution of a single P. aeruginosa isolate characterized by stepwise acquisition of two de-novo genetic resistance mechanisms over the course of treatment. We found a novel deletion affecting the ampC repressor ampD and neighboring gene ampE, which associated with initial cefepime treatment failure. This was followed by acquisition of a porin nonsense mutation, OprD, associated with resistance to carbapenems. This study highlights the potential for in-host evolution of P. aeruginosa during bloodstream infections in severely immunocompromised patients despite appropriate antimicrobial therapy. In addition, it demonstrates the utility of WGS for understanding unusual resistance patterns in the clinical context. |
format | Online Article Text |
id | pubmed-10499174 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104991742023-09-14 In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia Spottiswoode, Natasha Hao, Samantha Sanchez-Guerrero, Estella Detweiler, Angela M. Mekonen, Honey Neff, Norma Macmillan, Henriette Schwartz, Brian S. Engel, Joanne DeRisi, Joseph L. Miller, Steven A. Langelier, Charles R. Front Cell Infect Microbiol Cellular and Infection Microbiology Multidrug-resistant (MDR) Pseudomonas aeruginosa has been declared a serious threat by the United States Centers for Disease Control and Prevention. Here, we used whole genome sequencing (WGS) to investigate recurrent P. aeruginosa bloodstream infections in a severely immunocompromised patient. The infections demonstrated unusual, progressive increases in resistance to beta lactam antibiotics in the setting of active treatment with appropriate, guideline-directed agents. WGS followed by comparative genomic analysis of isolates collected over 44 days demonstrated in host evolution of a single P. aeruginosa isolate characterized by stepwise acquisition of two de-novo genetic resistance mechanisms over the course of treatment. We found a novel deletion affecting the ampC repressor ampD and neighboring gene ampE, which associated with initial cefepime treatment failure. This was followed by acquisition of a porin nonsense mutation, OprD, associated with resistance to carbapenems. This study highlights the potential for in-host evolution of P. aeruginosa during bloodstream infections in severely immunocompromised patients despite appropriate antimicrobial therapy. In addition, it demonstrates the utility of WGS for understanding unusual resistance patterns in the clinical context. Frontiers Media S.A. 2023-08-30 /pmc/articles/PMC10499174/ /pubmed/37712060 http://dx.doi.org/10.3389/fcimb.2023.1241608 Text en Copyright © 2023 Spottiswoode, Hao, Sanchez-Guerrero, Detweiler, Mekonen, Neff, Macmillan, Schwartz, Engel, DeRisi, Miller and Langelier https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Spottiswoode, Natasha Hao, Samantha Sanchez-Guerrero, Estella Detweiler, Angela M. Mekonen, Honey Neff, Norma Macmillan, Henriette Schwartz, Brian S. Engel, Joanne DeRisi, Joseph L. Miller, Steven A. Langelier, Charles R. In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia |
title | In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia |
title_full | In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia |
title_fullStr | In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia |
title_full_unstemmed | In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia |
title_short | In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia |
title_sort | in host evolution of beta lactam resistance during active treatment for pseudomonas aeruginosa bacteremia |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499174/ https://www.ncbi.nlm.nih.gov/pubmed/37712060 http://dx.doi.org/10.3389/fcimb.2023.1241608 |
work_keys_str_mv | AT spottiswoodenatasha inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia AT haosamantha inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia AT sanchezguerreroestella inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia AT detweilerangelam inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia AT mekonenhoney inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia AT neffnorma inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia AT macmillanhenriette inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia AT schwartzbrians inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia AT engeljoanne inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia AT derisijosephl inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia AT millerstevena inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia AT langeliercharlesr inhostevolutionofbetalactamresistanceduringactivetreatmentforpseudomonasaeruginosabacteremia |